BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 29900560)

  • 1. Scoring system for risk stratification of viral reactivation during prophylactic antiviral treatment in Korean patients with hepatitis B undergoing anticancer chemotherapy: A multicenter study.
    Kim HY; Yoo JJ; Oh S; Yu SJ; Kim YJ; Yoon JH; Kim W; Jung YJ; Kim BH; Kim CM; Park JW; Lee JH
    J Med Virol; 2018 Oct; 90(10):1593-1603. PubMed ID: 29900560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive outcomes of on- and off-antiviral prophylaxis in hepatitis B patients undergoing cancer chemotherapy: A competing risks analysis.
    An J; Shim JH; Kim SO; Choi J; Kim SW; Lee D; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
    J Med Virol; 2016 Sep; 88(9):1576-86. PubMed ID: 26945543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.
    Law MF; Ho R; Cheung CK; Tam LH; Ma K; So KC; Ip B; So J; Lai J; Ng J; Tam TH
    World J Gastroenterol; 2016 Jul; 22(28):6484-500. PubMed ID: 27605883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir.
    Park H; Park JY; Kim SU; Kim DY; Han KH; Chon CY; Ahn SH
    World J Gastroenterol; 2013; 19(43):7671-9. PubMed ID: 24431895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical prediction of failure of Lamivudine prophylaxis for hepatitis B virus-infected patients undergoing cytotoxic chemotherapy for malignancy.
    Kim IK; Kim BG; Kim W; Kim D; Kim YJ; Yoon JH; Lee HS
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5511-9. PubMed ID: 22890764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis B virus reactivation in breast cancer patients undergoing chemotherapy: A review and meta-analysis of prophylaxis management.
    Liu Z; Jiang L; Liang G; Song E; Jiang W; Zheng Y; Gong C
    J Viral Hepat; 2017 Jul; 24(7):561-572. PubMed ID: 28072494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy.
    Yamauchi N; Maruyama D; Choi I; Atsuta Y; Sakai R; Miyashita K; Moriuchi Y; Tsujimura H; Kubota N; Yamamoto G; Igarashi T; Izutsu K; Yoshida S; Kojima K; Uchida T; Inoue Y; Tsukamoto N; Ohtsuka E; Suzuki S; Inaguma Y; Ichikawa S; Gomyo H; Ushijima Y; Nosaka K; Kurata M; Tanaka Y; Ueda R; Mizokami M; Kusumoto S
    Cancer Sci; 2021 May; 112(5):1943-1954. PubMed ID: 33576088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preemptive adefovir versus lamivudine for prevention of hepatitis B reactivation in chronic hepatitis B patients undergoing chemotherapy.
    Ho EY; Yau T; Rousseau F; Heathcote EJ; Lau GK
    Hepatol Int; 2015 Apr; 9(2):224-30. PubMed ID: 25788197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiviral efficacy of lamivudine versus entecavir in patients with hepatitis B virus-related advanced hepatocellular carcinoma.
    Shin HS; Kim SU; Park JY; Kim DY; Han KH; Chon CY; Baatarkhuu O; Ahn SH
    J Gastroenterol Hepatol; 2012 Sep; 27(9):1528-34. PubMed ID: 22497450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B.
    Lee KS; Kweon YO; Um SH; Kim BH; Lim YS; Paik SW; Heo J; Lee HJ; Kim DJ; Kim TH; Lee YS; Byun KS; Kim D; Lee MS; Yu K; Suh DJ
    Clin Mol Hepatol; 2017 Dec; 23(4):331-339. PubMed ID: 28946736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An optimized antiviral modification strategy for prevention of hepatitis B reactivation in patients undergoing prophylactic lamivudine and chemotherapy: a pilot study.
    Wu XY; Li X; Chen ZH; Wen JY; Lin Q; Xing YF; Dong M; Wei L; Wang TT; Chen J; Lin ZX; Wan XB; Ruan DY; Ma XK
    Tumour Biol; 2013 Apr; 34(2):909-18. PubMed ID: 23269606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B.
    Huang YH; Hsiao LT; Hong YC; Chiou TJ; Yu YB; Gau JP; Liu CY; Yang MH; Tzeng CH; Lee PC; Lin HC; Lee SD
    J Clin Oncol; 2013 Aug; 31(22):2765-72. PubMed ID: 23775967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response.
    Woo HY; Park JY; Bae SH; Kim CW; Jang JY; Tak WY; Kim DJ; Kim IH; Heo J; Ahn SH
    Clin Mol Hepatol; 2020 Jul; 26(3):352-363. PubMed ID: 32460460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease.
    Chen FW; Coyle L; Jones BE; Pattullo V
    Liver Int; 2013 Sep; 33(8):1203-10. PubMed ID: 23522150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of clinical efficacy and renal safety of telbivudine and entecavir in chronic hepatitis B patients receiving cytotoxic chemotherapy.
    Law ST; Lee MK; Lee AS; Tung Y; Li KK
    J Dig Dis; 2016 May; 17(5):325-33. PubMed ID: 27085094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.
    Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI
    J Gastroenterol Hepatol; 2010 Aug; 25(8):1374-80. PubMed ID: 20659226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of antiviral prophylaxis in HBsAg-negative, anti-HBc positive patients undergoing hematopoietic stem cell transplantation.
    Yoo JJ; Cho EJ; Cho YY; Lee M; Lee DH; Cho Y; Lee JH; Yu SJ; Yoon SS; Yoon JH; Kim YJ
    Liver Int; 2015 Dec; 35(12):2530-6. PubMed ID: 26053357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Comparison of Entecavir and Lamivudine for the Prophylaxis of Hepatitis B Virus Reactivation in Solid Tumor Patients Undergoing Systemic Cytotoxic Chemotherapy.
    Chen WC; Cheng JS; Chiang PH; Tsay FW; Chan HH; Chang HW; Yu HC; Tsai WL; Lai KH; Hsu PI
    PLoS One; 2015; 10(6):e0131545. PubMed ID: 26121480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testing for hepatitis B infection in prospective chemotherapy patients: a retrospective study.
    Wang Y; Luo XM; Yang D; Zhang J; Zhuo HY; Zhang J; Jiang Y
    World J Gastroenterol; 2013 Feb; 19(6):923-30. PubMed ID: 23429298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B surface antigen seroconversion after HBV reactivation in non-Hodgkin's lymphoma.
    Liu WP; Zheng W; Song YQ; Ping LY; Wang GQ; Zhu J
    World J Gastroenterol; 2014 May; 20(17):5165-70. PubMed ID: 24803836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.